[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100533414":3},{"organization":4,"outcomesModule":7,"designInfo":42,"detailedDescription":54,"studyPopulation":41,"armGroups":55,"interventions":68,"overallOfficials":78,"centralContacts":82,"locations":88,"responsibleParty":262,"collaborators":264,"id":274,"slug":41,"hasResults":275,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":275,"sex":281,"minAge":282,"maxAge":41,"enrollmentInfo":283,"targetDuration":41,"studyType":286,"phases":287,"briefSummary":289,"conditions":290,"keywords":292,"overallStatus":223,"whyStopped":41,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":305},{"fullName":5,"class":6},"Institut Curie","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":41},[9],{"measure":10,"description":11,"timeFrame":12},"Overall survival","OS rate for the main analysis (primary endpoint) is defined as the percentage of patients still alive 36 months after the randomization. If the patient is not present at the 36th month visit, survival data may be obtained by other means, such as telephone contact with the patient, his family, his current physician, or consulting local death registries.\n\nA non-comparative analysis will be conducted in the experimental arm, and the control arm will serve as reference.","36 months",[14,18,21,25,29,32,35,39],{"measure":15,"description":16,"timeFrame":17},"Number of metastatic sites at the time of the clinical\u002Fradiological relapse.","The number of metastatic sites upon clinical\u002Fradiological relapse will be defined post-hoc by the Adjudication Committee as the number of organs or systems in which metastases are detected at the time of the clinical\u002Fradiological relapse, among the following propositions: lymph nodes, bones, liver, lungs, central nervous system\u002Fmeninges, peritoneum, others.","Clinical\u002Fradiological relapse up to 36 months",{"measure":19,"description":20,"timeFrame":17},"Recurrence-free survival","RFS \\[recurrence-free survival\\], defined as the time from randomization to clinical\u002Fradiological relapse or death; PFS \\[progression-free survival\\], defined as the time from randomization to the first progression or death occurring after clinical\u002Fradiological relapse; 1L-PFS \\[first line PFS\\], defined as the time from clinical\u002Fradiological relapse to first progression or death ; 2L-PFS \\[second line PFS\\], defined as the time from first to second progression or death; progression being defined per RECIST criteria.",{"measure":22,"description":23,"timeFrame":24},"Overall response rate","Best ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) based on local investigator assessment according to RECIST 1.1, until first progression or last tumor assessment in the absence of progression. ORR will be reported with its 95% confidence interval by arm.","12 months",{"measure":26,"description":27,"timeFrame":28},"Overal Survival","Overall Survival is defined as the time between randomization and death.","Up to 36 months",{"measure":30,"description":31,"timeFrame":17},"Performance Status Scale","Proportion of patients presenting with an altered general condition (PS ≥2) at first evidence of clinical or radiological relapse.\n\nThe population of interest consists in randomized patients.",{"measure":33,"description":34,"timeFrame":17},"EORTC Core Quality of Life questionnaire (EORTC-QLQ-C30) with the QLQ-BR42 module","The EORTC-QLQ-C30 questionnaire with the QLQ-BR42 is used to report health-related QoL in all included patients. Summary statistics of the scores for all functional\u002Fsymptom scales will be calculated at each assessment time point, according to the scoring procedure recommended by the EORTC.\n\nAll of the scales and single item measures range in score from 0 to 100. A high score for the functional scales and functional single items represents a high\u002Fhealthy level of functioning, whereas a high score for the symptom scales and symptom item represents a high level of symptomatology or problems.",{"measure":36,"description":37,"timeFrame":38},"5-level EQ-5D version (EQ-5D-5L)","y. Each state is referred to in terms of a 5 digit code. For example, state 11111 indicates no problems on any of the 5 dimensions, while state 12345 indicates no problems with mobility, slight problems with washing or dressing, moderate problems with doing usual activities, severe pain or discomfort and extreme anxiety or depression. A completely healthy patient would have a score of 11111. This 5-digit number can be converted into a score using a special algorithm that is not publicly available. This point value is called the EQ-5D-5L Index and represents the patient's health status.","Clinical\u002Fradiological relapse up to 24 months",{"measure":40,"description":40,"timeFrame":12},"Proportion of patients receiving local treatment for oligometastatic disease",null,{"allocation":43,"interventionModel":44,"interventionModelDescription":45,"primaryPurpose":46,"observationalModel":41,"timePerspective":41,"maskingInfo":47},"RANDOMIZED","PARALLEL","CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept to assess the clinical utility of ctDNA monitoring combined with 68Ga-FAPI-46-PET-CT imaging upon ctDNA detection for the surveillance of patients with a non-metastatic TNBC at high risk of relapse.\n\n68Ga-FAPI-46 is the radiopharmaceutical product. There is no study treatment (standard of Care).","DIAGNOSTIC",{"masking":48,"maskingDescription":49,"whoMasked":50},"TRIPLE","Upon detection of ctDNA during Step1, patients will be centrally assigned to the control or the experimental arm (1:1) using the eCRF.\n\nRandomization will be stratified by RCB score (I\u002FII vs. III\u002FNA because no neoadjuvant chemotherapy) and by time to molecular relapse (\\\u003C 12 months vs. ≥ 12 months between surgery and molecular relapse).",[51,52,53],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","The CUPCAKE trial will follow the Trials within Cohorts (TwiCs) approach. Non-metastatic TNBC patients at high risk of relapse will be included, after having signed a written informed consent, in a cohort allowing them to be followed by ctDNA monitoring every 4 months.\n\nFor each patient included, a ctDNA detection assay will be performed in blood samples every 4 months for a maximum of 24 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.\n\nFirst line therapy will not be started until a metastatic relapse has been found by imagining: no treatment will be started in the sole basis of a positive ctDNA test.\n\nIf, at any timepoint, ctDNA is detected (molecular relapse), patients will be randomized in a 1:1 ratio.\n\n* In the experimental arm, patients and their treating physician will be made aware of the molecular relapse (positive ctDNA detection results). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician. If\u002Fwhen a clinical\u002Fradiological relapse is observed, the patient performance status will be registered (secondary objective) and systemic or local treatments will be decided by physicians. These treatments could be informed by the genetic landscape of the relapse, assessed by ctDNA.\n* In the control arm, patients and their treating physician will not be made aware of the molecular relapse and will continue the standard surveillance with repeated ctDNA test every 4 months (blinded) for a maximum of 24 months from enrolement in the study. At the time of the clinical\u002Fradiological diagnosis of relapse, similar procedures will be performed (18F-FDG PET-CT, 68Ga-FAPI-46-PET-CT, and tumor genetic landscape assessment by ctDNA analysis).",[56,63],{"label":57,"type":58,"description":59,"interventionNames":60},"Experimental arm","EXPERIMENTAL","In the experimental arm, patients and their treating physician will be made aware of the molecular relapse (positive ctDNA detection results) in study steps 1 (ctDNA monitoring). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.",[61,62],"Diagnostic Test: ctDNA monitoring","Diagnostic Test: 68Ga-FAPI-46-PET-CT",{"label":64,"type":65,"description":66,"interventionNames":67},"Control arm","SHAM_COMPARATOR","In the control arm, patients and their treating physician will not be made aware of the molecular relapse and will continue the standard surveillance with repeated ctDNA test every 4 months (blinded). ). At the time of the clinical\u002Fradiological diagnosis of relapse, similar procedures will be performed (18F-FDG PET-CT, 68Ga-FAPI-46-PET-CT, and tumor genetic landscape assessment by ctDNA analysis).",[61,62],[69,74],{"type":70,"name":71,"description":72,"armGroupLabels":73,"otherNames":41},"DIAGNOSTIC_TEST","ctDNA monitoring","For each patient included, a ctDNA detection assay will be performed in blood samples every 4 months, while extra-plasma will be banked. ctDNA results will be available with a turnaround time of less than 3 weeks. When negative, ctDNA detection results will not be disclosed to patients nor clinicians.",[64,57],{"type":70,"name":75,"description":76,"armGroupLabels":77,"otherNames":41},"68Ga-FAPI-46-PET-CT","). To locate metastatic deposits, patients will be offered to undergo a whole-body imaging with 18F-FDG PET-CT and 68Ga-FAPI-46-PET-CT, in addition to any other workup considered as relevant by their treating physician.",[64,57],[79],{"name":80,"affiliation":5,"role":81},"François-Clément BIDARD","PRINCIPAL_INVESTIGATOR",[83],{"name":84,"role":85,"phone":86,"phoneExt":41,"email":87},"Anne-Claire COYNE","CONTACT","0147111515","drci.promotion@curie.fr",[89,106,119,133,147,160,173,186,199,209,222,235,249],{"facility":90,"status":91,"city":92,"state":41,"zip":93,"country":94,"countryCode":95,"cosmosGeoPoint":96,"geoPoint":101,"contacts":102},"Sainte-Catherine Institut du Caner Avignon-Provence","NOT_YET_RECRUITING","Avignon","84918","France","FR",{"type":97,"coordinates":98},"Point",[99,100],4.80892,43.94834,{"lat":100,"lon":99},[103,105],{"name":104,"role":85,"phone":41,"phoneExt":41,"email":41},"Julien GRENIER",{"name":104,"role":81,"phone":41,"phoneExt":41,"email":41},{"facility":107,"status":91,"city":108,"state":41,"zip":109,"country":94,"countryCode":95,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"Institut Bergonié","Bordeaux","33000",{"type":97,"coordinates":111},[112,113],-0.58046,44.84124,{"lat":113,"lon":112},[116,118],{"name":117,"role":85,"phone":41,"phoneExt":41,"email":41},"Monica ARNEDOS, MD",{"name":117,"role":81,"phone":41,"phoneExt":41,"email":41},{"facility":120,"status":91,"city":121,"state":41,"zip":122,"country":94,"countryCode":95,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"Centre Jean Perrin","Clermont-Ferrand","63011",{"type":97,"coordinates":124},[125,126],3.08682,45.77969,{"lat":126,"lon":125},[129,131],{"name":130,"role":85,"phone":41,"phoneExt":41,"email":41},"Marie-Ange MOURET-REYNIER",{"name":132,"role":81,"phone":41,"phoneExt":41,"email":41},"Marie-Ange MOURET-REYNIER, MD",{"facility":134,"status":91,"city":135,"state":41,"zip":136,"country":94,"countryCode":95,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Centre Leon Bérard","Lyon","69008",{"type":97,"coordinates":138},[139,140],4.84789,45.74906,{"lat":140,"lon":139},[143,145],{"name":144,"role":85,"phone":41,"phoneExt":41,"email":41},"Olivier TREDAN, MD",{"name":146,"role":81,"phone":41,"phoneExt":41,"email":41},"Olivier TREDAN",{"facility":148,"status":91,"city":149,"state":41,"zip":150,"country":94,"countryCode":95,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"Institut Paoli-Calmettes","Marseille","13009",{"type":97,"coordinates":152},[153,154],5.38107,43.29695,{"lat":154,"lon":153},[157,159],{"name":158,"role":85,"phone":41,"phoneExt":41,"email":41},"Renaud SABATIER, MD",{"name":158,"role":81,"phone":41,"phoneExt":41,"email":41},{"facility":161,"status":91,"city":162,"state":41,"zip":163,"country":94,"countryCode":95,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Institut du cancer de Montpellier","Montpellier","34298",{"type":97,"coordinates":165},[166,167],3.87635,43.61093,{"lat":167,"lon":166},[170,172],{"name":171,"role":85,"phone":41,"phoneExt":41,"email":41},"William JACOT, MD",{"name":171,"role":81,"phone":41,"phoneExt":41,"email":41},{"facility":174,"status":91,"city":175,"state":41,"zip":176,"country":94,"countryCode":95,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"CHU Nîmes","Nîmes","30900",{"type":97,"coordinates":178},[179,180],4.35788,43.83665,{"lat":180,"lon":179},[183,185],{"name":184,"role":85,"phone":41,"phoneExt":41,"email":41},"Frédéric FITENI, MD",{"name":184,"role":81,"phone":41,"phoneExt":41,"email":41},{"facility":187,"status":91,"city":188,"state":41,"zip":189,"country":94,"countryCode":95,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Hôpital Saint-Louis","Paris","75010",{"type":97,"coordinates":191},[192,193],2.3488,48.85341,{"lat":193,"lon":192},[196,198],{"name":197,"role":85,"phone":41,"phoneExt":41,"email":41},"Louis TEXEIRA, MD",{"name":197,"role":81,"phone":41,"phoneExt":41,"email":41},{"facility":200,"status":91,"city":188,"state":41,"zip":201,"country":94,"countryCode":95,"cosmosGeoPoint":202,"geoPoint":204,"contacts":205},"Hôpital Tenon","75020",{"type":97,"coordinates":203},[192,193],{"lat":193,"lon":192},[206,208],{"name":207,"role":85,"phone":41,"phoneExt":41,"email":41},"Joseph GLIGOROV",{"name":207,"role":81,"phone":41,"phoneExt":41,"email":41},{"facility":210,"status":91,"city":211,"state":41,"zip":212,"country":94,"countryCode":95,"cosmosGeoPoint":213,"geoPoint":217,"contacts":218},"Centre Eugène Marquis","Rennes","35000",{"type":97,"coordinates":214},[215,216],-1.67431,48.11109,{"lat":216,"lon":215},[219,221],{"name":220,"role":85,"phone":41,"phoneExt":41,"email":41},"Thibault DE LA MOTTE ROUGE, MD",{"name":220,"role":81,"phone":41,"phoneExt":41,"email":41},{"facility":5,"status":223,"city":224,"state":41,"zip":225,"country":94,"countryCode":95,"cosmosGeoPoint":226,"geoPoint":230,"contacts":231},"RECRUITING","Saint-Cloud","92340",{"type":97,"coordinates":227},[228,229],2.20289,48.84598,{"lat":229,"lon":228},[232,233],{"name":80,"role":85,"phone":41,"phoneExt":41,"email":41},{"name":234,"role":81,"phone":41,"phoneExt":41,"email":41},"François-Clément BIDARD, MD",{"facility":236,"status":91,"city":237,"state":41,"zip":238,"country":94,"countryCode":95,"cosmosGeoPoint":239,"geoPoint":243,"contacts":244},"ONCOPOLE Claudius Regaud","Toulouse","31059",{"type":97,"coordinates":240},[241,242],1.44367,43.60426,{"lat":242,"lon":241},[245,247],{"name":246,"role":85,"phone":41,"phoneExt":41,"email":41},"Florence DALENC, MD",{"name":248,"role":81,"phone":41,"phoneExt":41,"email":41},"Florence DALENC",{"facility":250,"status":91,"city":251,"state":41,"zip":252,"country":94,"countryCode":95,"cosmosGeoPoint":253,"geoPoint":257,"contacts":258},"Institut de cancérologie de Lorraine","Vandœuvre-lès-Nancy","54519",{"type":97,"coordinates":254},[255,256],6.17114,48.66115,{"lat":256,"lon":255},[259,261],{"name":260,"role":85,"phone":41,"phoneExt":41,"email":41},"Vincent MASSARD, MD",{"name":260,"role":81,"phone":41,"phoneExt":41,"email":41},{"type":263,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR",[265,267,270,272],{"name":266,"class":6},"National Research Agency, France",{"name":268,"class":269},"Roche Pharma AG","INDUSTRY",{"name":271,"class":269},"Personalis Inc.",{"name":273,"class":6},"UNICANCER","100533414",false,"NCT06225505","Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)","Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial","CUPCAKE","Inclusion Criteria:\n\n1. Patients must have signed a written informed consent before inclusion\n2. Patients must be female ≥ 18 years old\n3. Patients diagnosed with a non-metastatic TNBC (ER \\& PR \\\u003C10%, HER2- per ASCO\u002FCAP guidelines). Patients must have been previously evaluated by a 18F-FDG PET-CT or a bone scintigraphy combined with a thorax, abdomen and pelvis CT scan with contrast\n4. Patients who have undergone surgery with curative intent for their non-metastatic TNBC. Surgery must have been performed between 3 to 9 months before inclusion. Patients must have initiated their adjuvant therapy, whenever indicated, since at least 12 weeks. For patients receiving an experimental adjuvant treatment in a clinical trial, any intervention planned as part of this trial must be completed before inclusion.\n5. High-risk primary tumor, defined as:\n\n   1. Lack of pathological complete response after neoadjuvant chemotherapy (RCB I, II or III; RCB I being capped to a maximum of 30% of included patients) OR, in the absence of neoadjuvant chemotherapy,\n   2. Stage IIB-III (i.e., T2N1, any T3-T4, any N2-3) OR\n   3. Any loco-regional relapse occurring after a prior ipsilateral, curatively treated TNBC\n6. No sign of local or distant relapse, as per investigator assessment\n7. Performance status \\\u003C 2\n8. Available FFPE tumor block with \\> 10% cellularity or 11 tumor sections with \\>10% cellularity\n9. Patient able to comply with protocol requirements\n10. Patients covered by a health insurance\n\nExclusion Criteria:\n\n1. Any uncontrolled disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding or any other medical condition that, in the opinion of the investigator, interferes with the trial procedures\n2. Male participants\n3. Patients with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient informed consent.\n4. Patients who have difficulty undergoing trial procedures for geographic, social or psychological reasons\n5. Person deprived of liberty or under guardianship\n6. History of another primary malignancy except for the following :\n\n   1. Basal cell carcinoma or any in situ carcinoma treated with curative intent\n   2. Any stage I-II malignancy treated with curative intent with no evidence of active disease in the last five years\n7. For step #2 (randomization after ctDNA detection): clinical\u002Fradiological metastatic relapse before the detection of the molecular relapse.","FEMALE","18 Years",{"count":284,"type":285},450,"ESTIMATED","INTERVENTIONAL",[288],"NA","CUPCAKE is a randomized, non-comparative, multicenter, proof-of-concept phase II trial, using the Trials within Cohorts concept(1) to assess the clinical utility of ctDNA monitoring combined with 68Ga-FAPI-46-PET-CT imaging upon ctDNA detection for the surveillance of patients with a non-metastatic TNBC at high risk of relapse.\n\nThe study has two steps. In Step 1, patients who have completed the treatments for a localized TNBC will undergo ctDNA monitoring every \\~4 months (± 2 weeks). In Step 2, patients for whom ctDNA will be detected will then be randomized between an observation arm, in which monitoring will continue until the detection of a clinical relapse, and an experimental arm, in which the ctDNA detection will be revealed to both the patient and the clinician: patients will then undergo a 18F-FDG PET-CT and a 68Ga-FAPI-46-PET-CT, in addition to whatever workup the investigator will deem necessary.",[291],"Triple Negative Breast Cancer",[293,294,295],"Triple negative breast cancer","68Ga-FAPI-46","ctDNA","2026-01-20",{"date":298,"type":299},"2026-01-22","ACTUAL",{"date":301,"type":299},"2026-01-05",{"date":303,"type":285},"2031-08-03",{"name":5,"class":6},13]